Chinese herbal formulation PHY906

Drug Overview

Chinese herbal formulation PHY906 is a highly specialized, botanical medicine currently being studied as an advanced adjuvant therapy in cancer care. It is inspired by a 1,800-year-old traditional Chinese medicine called “Huang Qin Tang,” which has historically been used to treat stomach and bowel issues. In modern oncology, PHY906 is being developed to enhance the effectiveness and tolerability of standard cancer treatments. It acts as an Immunotherapy and a cytoprotectant (a substance that protects healthy cells).

Here are the key details about this investigational formulation:

• Generic Name: Chinese herbal formulation PHY906 (often referred to in research as YIV-906 or KD018). It is an extract of four specific herbs: Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, and Paeonia lactiflora.
• US Brand Names: YIV-906. It is an investigational drug and not yet available at standard pharmacies.
• Drug Class: Botanical Drug Candidate / Immunomodulator / Cytoprotectant.
• Route of Administration: Oral (capsules).
• FDA Approval Status: Currently investigational. While it received “Orphan Drug Designation” from the FDA in 2018 for advanced liver cancer, it is not yet fully FDA-approved for standard public use. It is actively being studied in advanced clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand PHY906, it is helpful to look at how it interacts with the body’s immune system and digestive tract. PHY906 is not designed to kill cancer cells directly by itself. Instead, it is an Immunotherapy and a broad-spectrum enhancer. It works at the molecular level in a few key ways:

1. Boosting the Immune System to Fight Cancer: PHY906 helps change the environment inside a tumor. It turns on specific signaling pathways (like IRF5, IFN, and JAK/STAT) that switch the tumor from a state of hidden, chronic inflammation to a state of acute inflammation. This acts like a biological alarm. It also helps change macrophages (a type of white blood cell) into a specific form (M1-like) that actively attacks and rejects the tumor.
2. Protecting the Digestive System: Many chemotherapy drugs severely damage the stomach and intestines. PHY906 blocks inflammatory signals (like NF-κB and COX-2) in the gut. By calming these signals, it significantly reduces severe side effects like diarrhea, nausea, and vomiting caused by chemotherapy and radiation.
3. Enhancing Drug Absorption: PHY906 briefly blocks certain enzymes in the liver and intestines (like CYP3A4). By doing this, it helps oral chemotherapy drugs stay in the bloodstream longer, allowing more of the cancer-fighting medicine to reach the tumor.

FDA-Approved Clinical Indications

Because PHY906 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being heavily researched in clinical trials for the following areas:

• Oncological Uses (In Clinical Trials):
  • Hepatocellular Carcinoma (Liver Cancer): Used alongside targeted therapies like sorafenib or chemotherapy like capecitabine to improve survival rates and reduce side effects.
  • Pancreatic Cancer: Used with chemotherapy to help patients who have not responded to initial treatments.
  • Colorectal Cancer: Used alongside strong chemotherapy drugs (like irinotecan) to prevent severe, life-threatening diarrhea and gut damage.
• Non-oncological Uses:
  • While its ancient formula was historically used for general gastrointestinal distress (cramps, diarrhea, vomiting), modern clinical development is strictly focused on its use as an aid in cancer treatment.

Dosage and Administration Protocols

Because PHY906 is designed to be taken with other chemotherapy drugs, its schedule is usually matched to the primary cancer treatment. It is taken as an oral pill, not an intravenous drip.

Clinical Efficacy and Research Results

Recent clinical studies (extending through the 2020-2025 period) have shown promising results for PHY906 as an adjuvant therapy, particularly for patients with advanced liver and pancreatic cancers.

• Liver Cancer (Hepatocellular Carcinoma): In a recent Phase II trial combining PHY906 with the chemotherapy drug capecitabine, patients achieved a median overall survival of 6 months, with over 51% of patients surviving past the 6-month mark. For patients who had not received any prior systemic treatments, the median overall survival jumped to over 9 months. Additionally, the CALM trial (completed in late 2024) extensively evaluated PHY906 in combination with sorafenib for Hepatitis B-positive liver cancer patients, aiming to prove its ability to extend life and improve comfort.
• Pancreatic Cancer: In a Phase II study for advanced pancreatic cancer patients who had failed standard therapies, the combination of PHY906 and capecitabine resulted in a median overall survival of roughly 21.6 weeks. About 44% of these patients survived beyond 6 months, which is a notable improvement in a highly aggressive disease setting.
• Quality of Life: Across multiple trials, PHY906 consistently lowered the rates of severe (Grade 3 or 4) nausea, vomiting, and diarrhea that usually force patients to stop taking their life-saving chemotherapy.

Safety Profile and Side Effects

PHY906 is a botanical formulation that is generally well-tolerated. Most side effects reported in clinical trials are actually caused by the harsh chemotherapy drugs it is paired with, rather than the herbal medicine itself.

Common Side Effects (>10%)

• Fatigue: Mild tiredness and lethargy.
• Mild Digestive Issues: Occasional mild nausea, bloating, or abdominal pain. (Note: PHY906 typically reduces the severe diarrhea caused by chemotherapy, though mild diarrhea can still occur).
• Lab Changes: Temporary drops in hemoglobin (red blood cells) or temporary rises in liver enzymes (AST/ALT).

Serious Adverse Events

• Severe side effects directly linked to PHY906 are extremely rare. In clinical trials, the severe events (like severe drops in white blood cells or major liver toxicity) are generally attributed to the primary chemotherapy agents (like irinotecan or sorafenib).

Black Box Warning: There is no FDA Black Box Warning for this investigational botanical agent.

Management Strategies

• If blood counts drop too low or liver enzymes spike, the medical team will usually pause the primary chemotherapy and the PHY906 until the body recovers.
• Patients experiencing mild nausea or bloating are encouraged to eat smaller, more frequent meals.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

PHY906 has a unique connection to tissue regeneration in the digestive tract. Radiation and strong chemotherapy drugs destroy the delicate lining of the intestines. In advanced preclinical studies, researchers discovered that PHY906 promotes the rapid repopulation of intestinal stem cells and progenitor cells. By stimulating a biological communication route known as the “Wnt signaling pathway,” PHY906 signals the body to quickly grow new, healthy tissue in the gut. This regenerative property allows the intestines to heal much faster from the toxic damage of cancer treatments.

Patient Management and Practical Recommendations

To ensure the highest safety and the best possible outcome during a clinical trial involving PHY906, patients should follow specific guidelines.

Pre-treatment Tests to be Performed

• Complete Blood Count (CBC): To ensure white blood cells, red blood cells, and platelets are at safe levels before starting.
• Liver and Kidney Function Tests: To check baseline organ health, specifically focusing on liver enzymes (AST, ALT, and Bilirubin).
• Hepatitis Screening: Testing for Hepatitis B or C is common, especially for patients taking this drug for liver cancer.
• Pregnancy Test: Required for women of childbearing age, as the accompanying chemotherapy drugs can harm an unborn baby.

Precautions During Treatment

• Because PHY906 works by altering how the body processes other chemicals, it is vital to track how the liver is handling the combination of drugs. Routine blood work will be required.

“Do’s and Don’ts” List

• DO swallow the capsules whole with a full glass of water.
• DO tell your medical team about every single medication you take, including over-the-counter vitamins.
• DON’T take any other herbal supplements, traditional medicines, or high-dose vitamins while taking PHY906, as they might interfere with how the treatments work.
• DON’T skip doses of either your primary chemotherapy or your PHY906 without speaking to your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Chinese herbal formulation PHY906 (YIV-906) is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.